(注册人名称的英文翻译) | |||||||||||||||||
c/o Stratasys, | 股份有限公司 | ||||||||||||||||
9600西76th街 | |||||||||||||||||
伊甸园普雷里 | 明尼苏达州 | ||||||||||||||||
55344 | |||||||||||||||||
请选择注册人是否按Form 20-F或Form 40-F覆盖提交年度报告。 Form 20-F [X] Form 40-F [] |
附件 数量 | 文件说明 | ||||
99.1 | 为截至2024年6月30日的Stratasys未经审计的简明合并财务报表,截至和截至2024年6月30日的财务状况。 | ||||
99.2 | Stratasys对截至2024年6月30日的三个和六个月的经营业绩和财务状况进行审查 | ||||
EX-101.INS | IXBRL分类标记实例文档-实例文档不在交互式数据文件中显示,因为其XBRL标记嵌入在内联XBRL文档中 | ||||
EX-101.SCH | IXBRL分类标记扩展模式文档 | ||||
EX-101.CAL | IXBRL分类标记计算链接基准文档 | ||||
EX-101.DEF | IXBRL分类扩展定义链接基础文档 | ||||
EX-101.LAb | IXBRL分类标签链接基础文档 | ||||
EX-101.PRE | IXBRL分类演示链接基础文档 | ||||
EX-104 | 封面交互数据文件-封面交互数据文件不在交互数据文件中显示,因为其XBRL标签嵌入在内联XBRL文档中 |
stratasys有限公司 | ||||||||
Loss after tax for FY2024 was US$8800万, a 7% increase compared to US$8190万 for FY2023. The net loss attributable to ordinary shareholders was 8.91 US cents per share for FY2024, compared with 10.53 US cents per share for FY2023. Conference Call There will be a webcast today, beginning at 8.30am AESt (Thursday, August 29); 6.30pm EDt (Wednesday, August 28). It can be accessed via: https://webcast.openbriefing.com/msb-fyr-2024/ The archived webcast will be available on the Investor page of the Company’s website: www.mesoblast.com About Mesoblast Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late- stage product candidates which respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process. Mesoblast has a strong and extensive global intellectual property portfolio with protection extending through to at least 2041 in all major markets. The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide. Mesoblast is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease, biologic-resistant inflammatory bowel disease, and acute respiratory distress syndrome. Rexlemestrocel-L is in development for advanced chronic heart failure and chronic low back pain. Two products have been commercialized in Japan and Europe by Mesoblast’s licensees, and the Company has established commercial partnerships in Europe and China for certain Phase 3 assets. Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see www.mesoblast.com, LinkedIn: Mesoblast Limited and Twitter: @Mesoblast References / Footnotes 1. Jagasia m et al. Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial. Blood. 2020 May 14; 135(20): 1739–1749 2. Abedin S, et al. Ruxolitinib resistance or intolerance in steroid-refractory acute graft versus-host disease — a real-world outcomes analysis. British Journal of Haematology, 2021;195:429–43. 3. Wittenberg RE, Gauvreau k, Leighton J, Moleon-Shea m, Borow Km, Marx GR, Emani Sm, Prospective randomized controlled trial of the safety and feasibility of a novel mesenchymal precursor cell therapy in hypoplastic left heart syndrome, JTCVS Open Volume 16, Dec 2023, doi: https://doi.org/10.1016/j.xjon.2023.09.031 4. Symons JD, Deeter L, Deeter N, et al. Effect of continuous-flow left ventricular assist device support on coronary artery endothelial function in ischemic and nonischemic cardiomyopathy. Cir Heart Fail 2019; 12:e006085. DOI: 10.1161/CIRCHEARTFAILURE.119.006085. 5. Using Reserve Bank of Australia (RBA) published exchange rate from June 30, 2024 of 1A$:0.6624US$. 6. TEMCELL® HS Inj. is a registered trademark of JCR Pharmaceuticals Co. Ltd. 7. TEMCELL sales by our Licensee are recorded in Japanese Yen before being translated into USD for the purposes of calculating the royalty paid to Mesoblast. Results have been adjusted for the movement of the USD to Japanese Yen exchange rate from 1USD:140.01 Yen for the twelve months ended June 30, 2023 to 1USD:151.75 Yen for the twelve months ended June 30, 2024. Forward-Looking Statements This press release includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our | 签字人: | /s/ Eitan Zamir | ||||||
名称: | Eitan Zamir | |||||||
标题: | 致富金融(临时代码) - 首席财务官 |